UNSPSC 51283934: Sulfatrozole

This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H12N4O3S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G91KDP4M35, chemically known as n1-(4-ethoxy-1,2,5-thiadiazol-3-yl)sulfanilamid but generally known as sulfatrozole, which bears US NIH Compound Identifier 216260. European Medicines Agency schedules Sulfatrozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10735MIG.

UNSPSC 51283934 Sulfatrozole (Commodity) shows minimal recent state and local procurement activity aligned with its nominal scope. The code represents a single pharmaceutical active ingredient, yet the two recent opportunities posted under it are unrelated to sulfatrozole: the Illinois Department of Public Health's awarded contract supplies doxycycline hyclate and ciprofloxacin hydrochloride tablets through a piggyback arrangement with Chartwell Rx LLC, while Seminole County, Florida's procurement addresses naloxone and drug deactivation systems. State and local purchasing systems often apply broader codes or legacy category tags to pharmaceutical acquisitions regardless of the specific active ingredient, and these records suggest the code is being used as a catch-all for pharmaceutical supply rather than for sulfatrozole specifically. No open solicitations for sulfatrozole itself appear in the recent opportunities block.

The Illinois Department of Public Health awarded a $2,999,999.11 contract over 12 months plus two optional renewal years to Chartwell Rx LLC in August 2026 through an Invitation for Bid process under the MMCAP Infuse cooperative purchasing vehicle. Seminole County's July 2026 IFB for naloxone and deactivation systems targets 1,900 annual units of naloxone and 800 units of safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year initial term plus one-year renewal. Activity is concentrated in Florida and Illinois, though the mismatch between the code's pharmaceutical ingredient designation and the actual goods being procured suggests either miscoding by the issuing bodies or the code's application to general pharmaceutical supply categories rather than sulfatrozole as a distinct product line.